News | February 09, 2023
JB Pharma records revenue growth of 32% to Rs. 793 Cr in Q3 FY23
Profit after Tax stood at Rs. 106 crore as compared to Rs. 84 crore registering growth of 26%
Profit after Tax stood at Rs. 106 crore as compared to Rs. 84 crore registering growth of 26%
The Survey highlighted that Indian pharmaceutical exports achieved a healthy growth of 24 per cent in FY21 and expressed hope that India’s domestic pharmaceutical market is estimated to grow to US $65 billion by 2024 from estimated US $41 billion in 2021
It will help upgrade the infrastructure and technologies of the country's biopharmaceuticals and in-vitro diagnostic industry
Standalone Q3 FY23 revenue stood at Rs. 626.5 crore as against Rs. 594.8 crore, a growth of 5% YoY
The issue with a face value of Rs 10 per equity share consists of a fresh issue of equity shares worth up to Rs 400 crore
The top 15 Indian pharma players have continued to experience anaemic growth in the US market over the five years ended FY22
South Asia’s largest exhibition for pharma brought together over 50,000 visitors from across the globe
Fredun received one-year contract worth Rs. 65 crores from a Southeast Asian country for Pharma exports
The show will be a part of the India Pharma Week, a marquee celebration catering to every need of the pharma community attendees
Within the API segment, ~20% of the revenues came from the domestic market and ~80% from the exports market
Subscribe To Our Newsletter & Stay Updated
